Meropenem For Ceftazidime-Avibactam—Resistant K. pneumoniae

Article

Researchers from the University of Pittsburgh find a way to successfully treat a patient with ceftazidime-avibactam-resistant Klebsiella pneumoniae.

Clinicians used meropenem to successfully treat a patient with bacteremia due to Klebsiella pneumoniae that carried a mutation in the blaKPC-3 gene, and was resistant to ceftazidime-avibactam.

Related Videos
Related Content
Food Preparation Safety: Tips to Avoid Foodborne Illness During Thanksgiving

Food Preparation Safety: Tips to Avoid Foodborne Illness During Thanksgiving

November 14th 2023
Article
Vaccine Race: The Pfizer Vaccine with William Schaffner, MD

Vaccine Race: The Pfizer Vaccine with William Schaffner, MD

November 16th 2020
Podcast
pneumococcal vaccine

Merck's Adult Pneumococcal Conjugate Vaccine Shows Promise in Phase 3 Trials

August 2nd 2023
Article
COVID-19 Vaccine Race: FDA Advisory Committee Meeting with Donald Alcendor, PhD

COVID-19 Vaccine Race: FDA Advisory Committee Meeting with Donald Alcendor, PhD

October 26th 2020
Podcast
Texas Judge Rules Employers Shouldn’t Be Required to Cover HIV PrEP

Texas Judge Rules Employers Shouldn’t Be Required to Cover HIV PrEP

September 8th 2022
Article
FDA Lifts Clinical Hold of Lenacapavir for HIV Treatment and Prevention

FDA Lifts Clinical Hold of Lenacapavir for HIV Treatment and Prevention

May 18th 2022
Article
© 2024 MJH Life Sciences

All rights reserved.